Equities Analysts Offer Predictions for Sanofi Q1 Earnings

Sanofi (NASDAQ:SNY) – Equities researchers at Zacks Research lowered their Q1 2027 earnings per share estimates for Sanofi in a research report issued on Friday, October 10th. Zacks Research analyst Team now forecasts that the company will earn $1.12 per share for the quarter, down from their prior estimate of $1.13. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q2 2027 earnings at $1.18 EPS and FY2027 earnings at $5.03 EPS.

A number of other analysts have also recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Barclays restated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Sanofi in a research report on Wednesday, October 8th. Morgan Stanley upgraded Sanofi from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Finally, JPMorgan Chase & Co. upgraded Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $62.67.

Sanofi Stock Up 1.5%

Sanofi stock opened at $48.80 on Monday. The stock has a market cap of $119.83 billion, a PE ratio of 11.73, a price-to-earnings-growth ratio of 1.17 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. Sanofi has a one year low of $44.62 and a one year high of $60.12. The stock has a fifty day moving average of $48.29 and a 200 day moving average of $49.70.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm’s revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.73 EPS.

Institutional Trading of Sanofi

Several institutional investors have recently made changes to their positions in SNY. Ameritas Advisory Services LLC purchased a new stake in shares of Sanofi during the second quarter worth about $28,000. Accent Capital Management LLC purchased a new stake in shares of Sanofi during the first quarter worth about $29,000. Eastern Bank grew its position in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA purchased a new stake in shares of Sanofi during the first quarter worth about $33,000. Finally, Golden State Wealth Management LLC grew its position in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock worth $35,000 after purchasing an additional 545 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.